Downloads: 10
Research Paper | Obstetrics and Gynecology | Volume 13 Issue 10, October 2024 | Pages: 965 - 968 | India
Efficacy and Safety of Oral Mifepristone as a Cervical Ripening Agent for Labor Induction in Low-Risk Full-Term Live Pregnancies Beyond 40 Weeks of Gestation: A Randomized Controlled Study
Abstract: This study evaluates the efficacy and safety of oral mifepristone as a cervical ripening agent for inducing labor in low-risk, full-term live pregnancies beyond 40 weeks of gestation. In this randomized controlled trial, 100 pregnant women were equally divided into two groups: the study group receiving 200 mg oral mifepristone and the control group undergoing expectant management. The primary outcomes measured were improvement in Bishop's score within 24-48 hours and the onset of labor within 72 hours. Secondary outcomes included allocation-to-delivery interval, the requirement for additional labor inducers, maternal and neonatal outcomes, and mode of delivery. Results showed significant improvements in cervical ripening, reduced need for additional labor inducers, and a shorter induction-to-delivery interval in the mifepristone group. Mifepristone demonstrated excellent safety and efficacy in inducing labor with minimal side effects, suggesting its potential role as a primary agent in labor induction protocols.
Keywords: Mifepristone, Cervical ripening, Term pregnancy, Labor induction, Pregnancy outcomes
How to Cite?: Dr. Nikita Yadav, Dr. Hanslata Gehlot, Dr. Rakesh Bagri, "Efficacy and Safety of Oral Mifepristone as a Cervical Ripening Agent for Labor Induction in Low-Risk Full-Term Live Pregnancies Beyond 40 Weeks of Gestation: A Randomized Controlled Study", Volume 13 Issue 10, October 2024, International Journal of Science and Research (IJSR), Pages: 965-968, https://www.ijsr.net/getabstract.php?paperid=SR241010212021, DOI: https://dx.doi.org/10.21275/SR241010212021